Investigational drugs in systemic vasculitis.

about

Antineutrophil cytoplasmic antibody associated vasculitides with renal involvement: Open challenges in the remission induction therapy.

P2860

Q55340553-E1019AFC-49C9-4C20-A467-F6D079AB793D

P2860

Investigational drugs in systemic vasculitis.

Item

http://www.wikidata.org/entity/Q51834131

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Investigational drugs in systemic vasculitis.

@en

Investigational drugs in systemic vasculitis.

@nl

type

Item

label

Investigational drugs in systemic vasculitis.

@en

Investigational drugs in systemic vasculitis.

@nl

prefLabel

Investigational drugs in systemic vasculitis.

@en

Investigational drugs in systemic vasculitis.

@nl

P1476

Investigational drugs in systemic vasculitis.

@en

P2093

Adrien Mirouse

http://www.w3.org/2001/XMLSchema#string

Anne Claire Desbois

http://www.w3.org/2001/XMLSchema#string

Christian Pagnoux

http://www.w3.org/2001/XMLSchema#string

Cloé Comarmond

http://www.w3.org/2001/XMLSchema#string

David Saadoun

http://www.w3.org/2001/XMLSchema#string

P2860

Phosphodiesterase 4-targeted treatments for autoimmune diseases

A double-blind trial of colchicine in Behçet's syndrome

CTLA-4 can function as a negative regulator of T cell activation

Modulation of CLA, IL-12R, CD40L, and IL-2Ralpha expression and inhibition of IL-12- and IL-23-induced cytokine secretion by CNTO 1275

2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behçet's disease susceptibility loci

Management of Behçet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behçet disease.

Polyamine compound deoxyspergualin inhibits heat shock protein-induced activation of immature dendritic cells.

Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria.

P304

1049-1061

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/13543784.2017.1361928

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Patrice Cacoub

P577

2017-07-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28758504

http://www.w3.org/2001/XMLSchema#string

Investigational drugs in systemic vasculitis.

about

P2860

P2860

Investigational drugs in systemic vasculitis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698